Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus

Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus

This article addresses possible mechanisms for development of cardiovascular events (CVE) in type 2 diabetes mellitus (T2DM) patients treated with sulfonylurea derivatives (SU). Several problems are highlighted in this review, including molecular aspects of pancreatic and extrapancreatic action of t...

Full description

Saved in:

Bibliographic Details
Main Author:	Lyudmila Viktorovna Nedosugova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2013-06-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus sulfonylureas sur katp channel ischemic preconditioning
Online Access:	https://www.dia-endojournals.ru/jour/article/view/3753
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sulfonylureas in the modern strategy of therapy of type 2 diabetes
by: Lyudmila Viktorovna Nedosugova
Published: (2011-06-01)

Glibenclamide - profile of efficacy and safety
by: Lyudmila Viktorovna Nedosugova
Published: (2011-09-01)

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
by: Alla Vsevolodovna Rudakova
Published: (2011-09-01)

Kir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle‐crossing gate
by: Ryoko Kawashima, et al.
Published: (2025-08-01)

The frequency of hypoglycemia and cardiovascular disorders during therapy with sulfonylureas compared with other secretagogues: a systematic review
by: Aleksey Vadimovich Zilov, et al.
Published: (2010-06-01)

Feasibility of efficacious therapy of diabetes mellitus by sulfonylurea agents in neonates with KCNJII gene mutation: originalobservation
by: Andrey Olegovich Emel'yanov, et al.
Published: (2009-09-01)

Systematic Review of Cardiovascular Outcomes with Sulfonylureas, GLP-1 RA, and DPP-4 Inhibitors in Type 2 Diabetes Mellitus
by: Koo Thai Hau, et al.
Published: (2024-07-01)

The Effect of Glibenclamide on the Functional Activity of К<sub>ATP</sub> Channels of Cerebral Arteries in Rats with Streptozotocin Diabetes Mellitus
by: I. B. Sokolova, et al.
Published: (2024-09-01)

Medication time of metformin and sulfonylureas and incidence of cardiovascular diseases and mortality in type 2 diabetes: a pooled cohort analysis
by: Mansour Bahardoust, et al.
Published: (2025-03-01)

The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
by: N. A. Petunina, et al.
Published: (2024-09-01)

Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01)

Relationship between the efficacy of sulfonylurea therapy and structural variants of the ABCC8 (rs757110) and KCNJ11 (rs5219) genes in patients with type 2 diabetes mellitus with different phenotypes
by: I. А. Bondar’, et al.
Published: (2024-04-01)

Impact of duration of treatments with metformin and sulfonylureas, individually or in combination, on diabetic retinopathy among newly diagnosed type 2 diabetic patients: a pooled cohort’s analysis
by: Mansour Bahardoust, et al.
Published: (2025-01-01)

Characterization of four structurally diverse inhibitors of SUR2-containing KATP channels
by: Kangjun Li, et al.
Published: (2024-12-01)

REDUCTION OF CARDIOVASCULAR COMPLICATIONS OF MODERN HYPOGLYCEMIC THERAPY OF DIABETES MELLITUS TYPE 2: "FLORENTINE HERESY"
by: A. A. Aleksandrov
Published: (2016-01-01)

Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
by: Tatiana Ivanovna Romantsova, et al.
Published: (2010-03-01)

Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01)

MODY3 in the child with type 2 diabetes mellitus phenotype: case report
by: Tamara Leonidovna Kuraeva, et al.
Published: (2013-06-01)

Using Pharmacoepidemiology to Examine the Interplay of Sulfonylureas and Infection Risk in Patients With Diabetes Mellitus
by: Yu‐ying Wu, et al.
Published: (2025-04-01)

The impact of sulfonylureas on diverse ion channels: an alternative explanation for the antidiabetic actions
by: Xian-Tao Li, et al.
Published: (2025-06-01)

Diagnosis and Treatment of Neonatal Diabetes Caused by ATP-Channel Mutations: Genetic Insights, Sulfonylurea Therapy, and Future Directions
by: Michela Trada, et al.
Published: (2025-02-01)

Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy
by: Chiara Gulisano, et al.
Published: (2025-05-01)

Risk of oncological diseases in patients with diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2009-12-01)

Diabetes mellitus — metabolic preconditioning in protecting the heart from ischemic damage?
by: D. S. Kondratieva, et al.
Published: (2023-01-01)

Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

Neonatal diabetes mellitus due to a new KCNJ11 mutation - 10 years of the patient`s follow-up
by: Maja D Ješić, et al.
Published: (2021-06-01)

Do KATP channels have a role in immunity?
by: Stefan Feske, et al.
Published: (2024-11-01)

Integrated surgical management of neuroischemic diabetic foot syndrome, abdominal aortic aneurysm and renal artery lesionsin patients with diabetes mellitus type 2
by: Sergey Anatol'evich Terekhin, et al.
Published: (2011-12-01)

Correlation between plasma proBNP, echocardiographic and clinical parameters in patientswith type 2 diabetes mellitus
by: Irina Arkad'evna Bondar', et al.
Published: (2013-03-01)

Attitudes in patients with diabetes mellitus type 1 and type 2
by: Oleg Gennad'evich Motovilin, et al.
Published: (2012-12-01)

Chronic metabolic stress impairs lymphatic contractility via activation of KATP channels in a mouse model of Type-2 diabetes
by: Jorge A. Castorena-Gonzalez, et al.
Published: (2025-04-01)

Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register
by: I. V. Misnikova, et al.
Published: (2022-05-01)

Assessing the environmental risks of sulfonylurea pollutants: Insights into the risk priority and structure-toxicity relationships
by: Zhi-Cong He, et al.
Published: (2025-03-01)

ABCC8 Mutation Causing Permanent Neonatal Diabetes Mellitus in Early Infancy: A Case Report
by: Leul M. Manyazewal, et al.
Published: (2025-07-01)

Bioequivalence assessment of the two brands of glimepiride tablets
by: Jovanović Dušan, et al.
Published: (2006-01-01)

The role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus
by: Larisa Viktorovna Koshel', et al.
Published: (2009-12-01)

Lack of association between KCNJ11 (rs5219) and ABCC8 (rs757110) polymorphisms and sulphonylurea treatment response in type 2 diabetes patients in Novosibirsk region
by: Irina Arkad'evna Bondar, et al.
Published: (2015-03-01)

Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas
by: Wei‐Sheng Chen, et al.
Published: (2025-03-01)

The importance of stem cells in the treatment of type 1 diabetes, type 2 diabetes and diabetes complications
by: Monika Kamińska, et al.
Published: (2025-01-01)

Efficacy and Safety of Oral Antidiabetic Drugs in Type 2 Diabetes Mellitus with Chronic Kidney Disease
by: Retta C Sihotang, et al.
Published: (2018-09-01)